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Abstract
Members of protein families often share conserved structural subsites for interaction with chemically similar moieties
despite low sequence identity. We propose a core site-moiety map of multiple proteins (called CoreSiMMap) to discover
inhibitors and mechanisms by profiling subsite-moiety interactions of immense screening compounds. The consensus
anchor, the subsite-moiety interactions with statistical significance, of a CoreSiMMap can be regarded as a ‘‘hot spot’’ that
represents the conserved binding environments involved in biological functions. Here, we derive the CoreSiMMap with six
consensus anchors and identify six inhibitors (IC50,8.0 mM) of shikimate kinases (SKs) of Mycobacterium tuberculosis and
Helicobacter pylori from the NCI database (236,962 compounds). Studies of site-directed mutagenesis and analogues reveal
that these conserved interacting residues and moieties contribute to pocket-moiety interaction spots and biological
functions. These results reveal that our multi-target screening strategy and the CoreSiMMap can increase the accuracy of
screening in the identification of novel inhibitors and subsite-moiety environments for elucidating the binding mechanisms
of targets.
Citation: Hsu K-C, Cheng W-C, Chen Y-F, Wang H-J, Li L-T, et al. (2012) Core Site-Moiety Maps Reveal Inhibitors and Binding Mechanisms of Orthologous Proteins
by Screening Compound Libraries. PLoS ONE 7(2): e32142. doi:10.1371/journal.pone.0032142
Editor: Piero Andrea Temussi, Universita ` di Napoli Federico II, Italy
Received July 15, 2011; Accepted January 24, 2012; Published February 29, 2012
Copyright:  2012 Hsu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors are grateful to Core Facility for Protein Structural Analysis supported by National Core Facility Program for Biotechnology. Dr. Wen-Ching
Wang was supported by a grant from National Science Council (NSC98-2313-B-007-005-MY3, NSC98-3112-B-007-004). Dr. Yang was supported by National Science
Council, partial supports of Ministry of Education and National Health Research Institutes (NHRI-EX100-10009PI). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: moon@faculty.nctu.edu.tw (JMY); wcwang@mx.nthu.edu.tw (WCW)
. These authors contributed equally to this work.
Introduction
The expanding number of protein structures and advances in
bioinformatics tools have offered an exciting opportunity for
structure-based virtual screening in drug discovery [1]. Although
there are some successful agents in the antibiotic development, few
agents act at novel molecular binding sites to target multiple
antibiotic–resistant pathogenic bacteria [2,3]. However, screening
tools are often designed for one-target paradigm and the scoring
methods are highly target-dependent and energy-based. As a
result, they cannot consistently and persuasively identify true leads,
leading to a low success rate [4–6].
Orthologous proteins often perform similar functions, despite
low sequence identity. Importantly, they frequently share
conserved binding environments for interacting with partners.
These proteins and their interacting partners (inhibitors or
substrates) can be regarded as a pharmacophore family, which is
a group of protein-compound complexes that share similar
physical-chemical features and interaction patterns between the
proteins and their partners. Such a family is analogous to a protein
sequence family [7,8] and a protein structure family [9]. However,
the establishment of pharmacophores often requires a set of
known active ligands that were acquired experimentally [10–12].
Developing an efficient method for identifying new adaptive
inhibitors against multiple targets from public compound libraries
is therefore becoming an important task [13–15].
To address the above issues, we propose a core site-moiety map
to discover inhibitors and mechanisms of multiple targets from
large-scale docked compounds. The consensus anchors, which are
subsite-moiety interactions with statistical significance in site-
moiety maps of these proteins, represent the conserved binding
environments that are involved in biological functions. The new
method (called CoreSiMMap-based screening method) was
heavily modified and improved from that ‘‘SiMMap’’ in our
earlier work [16], which constructed a site-moiety map comprising
of anchors from a target protein and thousands of docked
compounds. An anchor contains three crucial elements, which are
conserved interacting residues that constitute a binding pocket
(part of the binding site), the preference of moieties, and a pocket-
moiety interaction type.
The major enhancements of the CoreSiMMap for multi-target
inhibitors from SiMMap are as follows: 1) we developed the robust
theoretical model for the SiMMap; 2) the CoreSiMMap is
designed for multiple target proteins by modifying the SiMMap
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e32142on a single target protein; 3) we added an anchor alignment
method to identify core binding environments (anchors) among
multiple targets to reveal binding mechanisms; 4) we added a rank-
based consensus score (RCS) of multiple targets to improve the
enrichment of true positives. Based on these enhancements and
modifications, the CoreSiMMap-based screening method is useful
to infer core pharmacophores both to identify adaptive inhibitors
of multiple targets and to improve screening accuracy.
Here, we have applied the CoreSiMMap strategy to discover
core pharmacophores and adaptive inhibitors of shikimate kinase
(SK) of Mycobacterium tuberculosis and Helicobacter pylori (MtSK and
HpSK) by screening large compound libraries. Mt causes
tuberculosis and killed 1.7 million people in 2006 [17]. Therefore,
it is becoming a major public health threat[18]. We first derived
core site-moiety maps that often represent the conserved binding
environment elements or ‘‘hot spots’’ among orthologous targets
based on virtual screening. In using core site-moiety maps, six
potent adaptive inhibitors of MtSK and HpSK with low IC50
values (,8.0 mM) were identified. Site-directed mutagenesis
revealed that the core pharmacophores often contribute to specific
pocket-moiety interaction anchors. These results reveal the
CoreSiMMap is useful to identify adaptive SK inhibitors and
provide insight into the binding mechanisms of compounds.
Results
Overview of CoreSiMMap
A CoreSiMMap is the consensus site-moiety maps, which
consist of several consensus anchors derived from multiple targets,
to represent essential features that are involved in the common
biological functions of these targets (Figs. 1 and 2). The following
criteria are considered for a CoreSiMMap: (1) the binding sites of
the screening targets share conserved physical-chemical features;
(2) pocket-moiety interaction profiles of these targets and well-
docked compounds are similar; and (3) the site-moiety maps of
these targets share comparable anchors (pharmacophores) with
respect to their sites and crucial protein-ligand interactions.
Figure 1 presents the major steps of the CoreSiMMap-based
method for orthologous targets (HpSK and MtSK). For each
target, we used the top 2% (,6000) of compounds obtained by
screening compound libraries to analyze target-compound inter-
action profiles (Fig. 1B) to establish the site-moiety maps and
Figure 1. Framework of CoreSiMMap-based screening method. In Step 1, GEMDOCK was used to generate docked poses for HpSK and MtSK
by screening compound libraries (Maybridge and NCI). For each target (HpSK or MtSK), the protein-compound interacting profile was derived by the
top 2% (,6,000) of compounds ranked by docking energy. In Step 3, conserved interactions of the target protein and chemical moieties of ligands
are identified to deduce the anchors of HpSK and MtSK. The CoreSiMMap is constructed based on the features that are conserved between
orthologous target site-moiety maps, which will be used to select candidate compounds for the enzymatic assay. Finally, the model is refined based
on the bioassay of candidate compounds.
doi:10.1371/journal.pone.0032142.g001
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significant Z-scores. The superimposed pharmacophore models
with anchors among orthologous proteins revealed overlapping
regions, which are regarded as ‘‘hot spots’’. A set of hot spots from
orthologous targets therefore form a core site-moiety map that
represents the conserved binding elements (Fig. 1E). After enzyme
inhibition assay, active and inactive compounds were used to
refine the CoreSiMMap model and core anchors.
CoreSiMMaps of HpSK and MtSK
The CoreSiMMap that has comparable spots or hot spots is
useful in providing biological insights and guiding the process of
drug discovery including hit search and lead optimization. Here,
we utilized the CoreSiMMap strategy to identify adaptive
inhibitors of MtSK and HpSK. The SK is the fifth enzyme in
the shikimate pathway and converts shikimate to shikimate 3-
phosphate[19]. The SK is an attractive target for the development
of new antimicrobial agents, herbicides, and antiparasitic agents
since it is essential to bacteria, fungi, and plants, but not animals
[20]. Because there are distinct binding pockets with or without
ligands for shikimate kinase, we sought to establish apo-form and
closed-form CoreSiMMaps of SKs (Fig. 2). We first generated the
apo-form SiMMaps of HpSK (6 anchors) and MtSK (7 anchors),
allowing us to derive the CoreSiMMap with 6 consensus anchors
(Figs. 2A and 2C). In parallel, the closed-form CoreSiMMap with
6 consensus anchors was also derived (Figs. 2B and 2D).
The apo-form and closed-form CoreSiMMaps have six
comparable anchors: E1, H1–H3, V1, and V2 (Figs. 2C and
2D). H1, H2, and V1 sit at the ATP site, while H3, V2, and E1 are
situated at the shikimate site (Figs. S1 and S2). The protein-ligand
relationship was analyzed for each hot spot; a set of chemically
related entities that contribute to intermolecular interactions were
then identified (Figs. 2E, S1, and S2). Our results support the
notion that a hot spot has a conserved binding environment with a
specific chemical-physical property, which can be used as a guide
in further lead optimization. The compounds moieties, anchors,
SiMMaps and CoreSiMMaps are available at http://simmap.life.
nctu.edu.tw/orthsimmap/.
Of the six consensus anchors (Fig. 2E), E1 is a negatively
charged pocket that interacts with R57 (R58 in MtSK), R116
Figure 2. Shikimate kinase CoreSiMMaps. (A) Superimposed apo-form anchors of HpSK and MtSK. (B) Superimposed closed-form anchors of
HpSK and MtSK. (C) The apo-form CoreSiMMap and (D) the closed-form CoreSiMMap include six consensus anchors derived from consensus anchors
(A) and (B), respectively. Each consensus anchor shares conserved residues between HpSK and MtSK and has the same interaction type of binding
environment. (E) Features of the six consensus anchors of the apo-form CoreSiMMap. Each of the T groups (T1–T4) represents a given chemical
moiety and T-O* indicates other chemical groups. H1, V1, and H2 are situated at the ATP-binding site, while H3, V2, and E1 are at the shikimate-
binding site. Each consensus anchor includes conserved interacting residues (N) and the major chemical moieties of the compound candidates.
doi:10.1371/journal.pone.0032142.g002
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arginines are highly conserved in SKs and are critical for binding
to shikimate [21] (Fig. 2, S1, and S2). The chemical entities on E1
consisted of carboxyl, sulfonate, and phosphate groups. H1 is
enclosed with a tight turn (Walker A motif) that binds the b-
phosphate of ATP [21]. The identified moieties were carboxylic
amide, sulfonate ester, carboxyl acid, and ketone (Fig. 2E). H2 is
located between H1 and H3 and possesses a hydrogen-bonding
environment from a Walker A motif (K14 and S15 in HpSK; K15
and S16 in MtSK) and a DT/SD motif (D31 and D33 in HpSK;
D32 and D34 in MtSK). Amide, ketone, sulfonate ester, and
azine-containing compounds fit into this pocket. H3 is situated
above the central sheet in which two conserved residues (D33, and
G80 in HpSK; D34, G80 in MtSK) contribute to H3. Amide,
sulfonate ester, and ester groups were frequently identified.
V1, which is adjacent to H1, bears a vdW-binding environment
and also contains residues from the Walker A motif. V2, which is
near H3, is situated at the border between shikimate and the
nucleotide binding regions. V1 and V2, allowing the interactions
with large chemical groups, prefer aromatic groups. Analysis of the
closed-form SiMMaps indicates that E114 and R116 (T115 and
R117 in MtSK) in LID are conserved interacting residues (Fig. 2E).
Analysis of the closed-form model shows that the four hot spots
(E1, H1, H2, and V1) occupy a similar region in the closed-form
pharmacophores. Given the closure of the LID region, E1, H2,
and V1, interact with a residue from LID [19,22]. On the other
hand, H3 and V2 were absent in the closed form, perhaps because
of its tight binding pocket.
Inhibitors and inhibition assay
Following the analyses of the SiMMap and the compound-
anchor-residue profiles (Fig. 3), we used the CoreSiMMap in post-
screening analysis to rescore docked compounds by the rank-based
consensus scoring (RCS [23]), which combines energy-based and
anchor-based scoring (Fig. 4). Since a compound that simulta-
neously docks into apo and closed-form binding sites of HpSK and
MtSK is regarded as a potentially useful hit, we selected common
top-ranked compounds from the closed-form and apo-form
CoreSiMMap analysis for subsequent bioassay. After compounds
were ranked by using RCS in both the Maybridge and the NCI
Figure 3. Interaction profiles between selected anchor residues and 27 tested compounds. (A) Anchor profile of tested compounds on
shikimate kinases. (B) Group I: NCI compounds (orange). (C) Group II: Maybridge compounds (yellow). (D) Group III: kinase inhibitors (cyan). The NCI
compounds consistently occupy anchors E1 and V2 at both ATP and shikimate sites. The NCI compounds except NSC45174 are competitive inhibitors
with both ATP and shikimate. For the Maybridge compounds, none form electrostatic interactions with R57 and R132 on the consensus anchor E1.
The two kinase compounds are located at the ATP site, which fact is consistent with the kinetic results that reveal that these compounds exhibited
competitive inhibition with ATP and noncompetitive inhibition with shikimate.
doi:10.1371/journal.pone.0032142.g003
Core Site-Moiety Map for Inhibitors and Mechanisms
PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e32142Figure 4. Ranks of active compounds using CoreSiMMap, energy-based, and combined scoring methods for apo and closed forms
of HpSK and MtSK.
doi:10.1371/journal.pone.0032142.g004
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were subjected to MtSK and HpSK inhibitory assays. Among
those, 10 compounds had IC50 #100 mM for both HpSK and
MtSK, of which six [NSC45611 (1), NSC162535 (2), NSC45612
(3), NSC45174 (4), NSC45547 (6), and NSC45609 (7)] had
IC50#10 mM. In parallel, 65 existing kinase inhibitors were tested
to evaluate their inhibitory effectiveness against shikimate kinase.
Of the two compounds [AG538 (5) and GW5074 (12)] that
showed inhibitory effects, AG538 (5) had a low IC50 value.
Enzymatic kinetic analysis revealed that NSC45611 (1),
NSC162535 (2), NSC45612 (3) and AG538 (5) were competitive
inhibitors of ATP, in agreement with the docked poses (Fig. 5). Of
these, NSC45611 (1), NSC162535 (2) and NSC45612 (3)
competed with shikimate and had low IC50 and aKi values,
showing potent inhibition.
We then further evaluated the binding and pharmacophore
modes of these inhibitors. Figure 6 shows that these three
compounds have lower IC50 (#10 mM) and fit well into five hot
spots (H1, V1, H3, V2, and E1). The compounds with
IC50$20 mM lack the negatively charged groups that are required
to form electrostatic interactions with arginines (R57 and R136 in
HpSK) on E1. On the other hand, kinase inhibitors AG538 (5)
and GW5074 (12) did not occupy the shikimate site. Moieties with
1–3 rings were present at V1 and V2, yielding a number of vdW
contacts. The binding groups of active inhibitors matched well
with the identified moieties that were found from the consensus
anchors. For example, the sulfonate groups of NSC162535 (2),
NSC45611 (1), and NSC45612 (3) were found to occupy H1. The
moieties of NSC162535 (2) (SO3
2 group), NSC45611 (1) (CO2
2
group), and NSC45612 (3) (CO2
2 group) occupied E1.
Consensus residues of CoreSiMMap and site-directed
mutagenesis
A consensus anchor of orthologous targets that is identified from
the conserved binding pockets has conserved interacting residues
and a specific physico-chemical property, which often engage in
specific enzymatic functions. We sought to investigate the roles of
identified consensus anchor residues of the CoreSiMMaps in
catalysis (Fig. 2). Each of the selected residues was replaced with
alanine and expressed in Escherichia coli. After purification using
affinity chromatography, all mutants migrated to a major band of
an apparent molecular mass of ,18 kDa in SDS-PAGE, as
expected. We first investigated mutants of E1 residues (R57,
R116, and R132) that contact with shikimate [19]. Enzymatic
analysis revealed that these arginines had extremely low activity
(Fig. 6G), suggesting their importance in catalysis. Indeed, R117 of
MtSK, which corresponds to R116 of HpSK, has thus been
suggested as a primary candidate to stabilize the transition-state
intermediate [24].
For the H3 (D33) and V2 (F48) residues, D33A completely lost the
enzymatic activity while F48A exhibited hardly any detectable
activity (1%, Fig. 6G). D33 and F48 are in direct contact with
shikimate.Moreimportantly,D33formsahydrogenbondwiththe3-
OH group of shikimate, which may increase the nucleophilicity of the
O atom or accept the proton from the 3-OH group of shikimate,
facilitating catalysis. E114A, a LID residue whose side chain faces the
solvent, retained 82% relative activity. On the other hand, the F48
side chain contacts with those from several residues nearby (V44,
E53, F56, R57 and P117), potentially forming a stable platform that
interacts with the ligand for a subsequent catalytic reaction.
Figure 5. Properties of some potent inhibitors of HpSK and MtSK. Docked poses of NSC45611, NSC162535, and NSC45612 are located at the
ATP site (H1, H2, and V1) and the shikimate site (H3, V2, and E1), and these inhibitors are competitive inhibitors of ATP and shikimate (SKM). AG538 is
a competitive inhibitor of ATP, in agreement with its docked pose.
doi:10.1371/journal.pone.0032142.g005
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nucleotide site. H1 residues are primarily from the Walker A motif
(P loop; residues 11–16, GSGKSS) that surrounds the phosphate
groups of the nucleotides. Of the two alanine mutants (S12A and
S15A), S12A retained 59% of the relative activity, while S15A had
extremely low activity (1%). The S15 side chain resides near the b-
phosphate of ADP. Furthermore, the adjacent lysine (K14)
corresponding to K15 of MtSK has been identified as a critical
catalytic residue in MtSK since its side chain points toward the c-
phosphate [24]. The other H2 mutant, D31A, retained 62% of the
relative activity, possibly because of its remoteness from the
phosphate group. For V1 that is just next to H1, several H1
residues are also shared by V1. Enzymatic analysis indicated that
M10A retained 38% relative activity. These site-directed muta-
genesis studies revealed that the critical conserved interacting
residues of a pocket-moiety interaction spot participated in
biological functions.
Analogues assay and CoreSiMMap
To verify the moiety preferences of consensus anchors, we
identified four analogues of NSC162535 (2) [NSC45547 (6),
NSC45609 (7), NSC37215, and NSC45208] for inhibitory
assays (Fig. 6H). NSC45547 (6) and NSC45609 (7) that occupy
E1 (SO3
2 group) and H1 (SO3
2 and NO2 groups) retained good
IC50 values (7.8 and 7.0 mM for HpSK; 3.4 and 2.0 mM for MtSK).
Conversely, NSC37215 and NSC45208, which cannot anchor at
E1, lost the inhibitory.
To evaluate the significance of the pocket-moiety interaction
preferences of consensus anchors in the CoreSiMMaps, we
performed clustering analysis on 27 inhibitory assay compounds
(Fig. 3). These compounds can be roughly clustered into three
groups. The potent inhibitors of Group I [NSC162535 (2),
NSC45609 (7), NSC45547 (6), NSC45174 (4), NSC45611 (1) and
NSC45612 (3)] match more than 5 consensus anchors (Fig. 3B).
Each of the Group II compounds [RH00037 (8), RH00016 (9),
GK01385 (10), and SPB01099 (11)] matches four of six anchors;
Group III comprises kinase inhibitors [AG538 (5) and GW5074
(12)] and these compounds match anchors at the ATP site. The
inactive compounds often match few consensus anchors in the
HpSK/MtSK (usually 4), in particular, E1 is the least seen anchor.
While the inhibitors of Group I and II match anchors at the ATP
site and the shikimate site, kinetic assay indicates competitive
inhibitions for ATP and shikimate acid (Fig. 5). The kinase
inhibitors of Group III occupied the anchors of the ATP site, and
only showed the competitive inhibitions for ATP. The pocket
environment of ATP is generally conserved in kinase family, and
Figure 6. Characterization of shikimate kinase inhibitors by enzyme assay, CoreSiMMaps, site-mutagenesis studies, and analogues.
(A–C) Structures of three inhibitors, NSC162535 (2), NSC45611 (1), and NSC45612 (3). (D–F) Relationships between anchors and docked mode of each
inhibitor for HpSK. These compounds consistently include two negative charge moieties (SO3
2 or CO2
2) that form hydrogen bonds with conserved
interacting residues of anchors E1 and H1. (G) Comparison of relative activities of HpSK mutants. The conserved interacting residues for each anchor
were mutated. R57, R132, R116, and F48 located in the shikimate site were critical for the enzymatic functions. (H) Potency of NSC162535 analogues.
The substitution moieties of analogues are indicated in black. Those that lack the E1 moiety greatly lost the inhibitory effects (IC50.100 mM).
doi:10.1371/journal.pone.0032142.g006
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multiple kinases, including AG538 (5), which is observed on
insulin-like growth factor-1 receptor (IGF-1R) [25], IR, EGFR
[26], and Src kinases [27].
We sought to evaluate the binding-site features of the apo and
closed forms that show a significant structural change because of
LID closure and domain movement [19,21,28]. Indeed, the apo-
form HpSK structure shows higher deviations in the LID region
and in the adenine binding loop region (residues 143–150) (Fig.
S3). Superimposition of the apo and closed HpSK structures
revealed a tight binding pocket, particularly for the shikimate
binding site. While the apo and closed forms had the same number
of consensus anchors (E1, H1, H2, H3, V1 and V2), the spatial
arrangements of these anchors were more packed in the closed
form (Figs. 2C and 2D). Residues (D31 and D33) that contribute
to H2 of the apo form were closer to each other in the closed
conformation, resulting in a lower volume at this pocket. Likewise,
the corresponding pocket at V2 surrounded by F48, G80, and
G81 in HpSK had less space in the closed form, hindering the
accommodation of large moieties in this pocket. The above
evidences demonstrate that the induced LID conformation of
shikimate kinases was sensitive in the structure-based drug
discovery strategy (Fig. 4). The CoreSiMMap, considering both
apo-form and close-form structures, can reduce the ill effects.
Accuracy of the CoreSiMMap-based screening method
We next evaluated the accuracy of energy-based and Cor-
eSiMMap-based scoring methods. The energy-based score
(docking energy) of a compound was generated using a docking
program, GEMDOCK [23,29]. The scoring function in GEM-
DOCK is piecewise linear potential (PLP), which is a simple
scoring function and is comparable to some energy-based scoring
functions in estimating binding affinities [30]. Here, we used the
hit rate and enrichment to assess the overall accuracy. The hit rate
is defined as Ah/Th (%) and the enrichment is (Ah/Th)/(A/T),
where Ah is the number of active compounds among the Th highest
ranking compounds (hit list), A is the total number of active
compounds in the database, and T is the total number of
compounds in the database. Here, Ah is 8 (hits, compounds with
IC50,100 mM) based on the bioassay results, and T is 6000
based on the 6000 top-ranked compounds from screening
databases. We computed the average of enrichments, defined
as
PA
i~1 ½(i=Ti
h)=(A=T) =A, where Ti
h is the number of compounds
in a hit list containing i active compounds.
As shown in Figure 7A, the CoreSiMMap-based scoring
method (solid lines) significantly outperformed the energy-based
scoring method (dashed lines), which is often used in docking tools,
when applied to apo-form HpSK and MtSK. The average
enrichments of 3.73 (HpSK), 1.59 (MtSK), and 2.74 (fusion of
HpSK and MtSK) were obtained using energy-based scoring
method, as compared to 11.18 (HpSK), 35.51 (MtSK), and 93.69
(fusion of HpSK and MtSK), obtained using the CoreSiMMap
scoring method. The average hit rates were 0.92% (HpSK), 0.21%
(MtSK), and 0.37% (fusion of HpSK and MtSK) using energy-
based scoring methods as compared to 34.13% (HpSK), 17.57%
(MtSK), and 67.02% (fusion of HpSK and MtSK) using the
CoreSiMMap score. Additionally, the CoreSiMMap-based RCS
strategy was more accurate than the SiMMap-based strategy for a
single target (HpSK or MtSK).
The CoreSiMMap scoring method can reduce the deleterious
effects of screening ligand structures that are rich in charged or
polar atoms. Generally, energy-based scoring functions favor the
selection of high-molecular-weight compounds that yield high
vdW potentials, as well as polar compounds that produce
hydrogen-bonding and/or electrostatic potentials [23]. The
average molecular weights of the 100 top-ranked compounds of
the CoreSiMMap-based and energy-based scoring methods were
459.9 and 532.6, respectively; the average numbers of polar atoms
Figure 7. Performance of CoreSiMMap method on apo-form HpSK and MtSK. (A) True-hit rates of energy-based and CoreSiMMap scoring
approaches. The CoreSiMMap scores (solid line) of adaptive inhibitors are significantly better than the energy-based scores (dashed line) for the 6000
top-ranked compounds by combining the Maybridge and NCI databases. (B) Distribution of number of polar atoms. (C) Molecular weights of top 100
compounds from CoreSiMMap scores and energy-based scores.
doi:10.1371/journal.pone.0032142.g007
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method) (Figs. 7B and 7C). The ranks of the 10 active compounds
were much higher in the CoreSiMMap-based scoring analysis
than in the energy-based analysis. Notably, NSC162535 (2) was
ranked as 1 and 1821 using the apo-form CoreSiMMap-based and
energy-based scoring methods, respectively (Fig. 4).
Discussion
By far the largest obstacle in structure-based drug discovery is
the relatively low hit rate of scoring methods owing to the lack of
adequate quantities of binding partners for a given target. The
accuracy of a given individual scoring function is generally
unknown and/or cannot be evaluated. The emphasis of the
CoreSiMMap-based screening method developed here is therefore
to provide a useful index to improve screening accuracy for the
identification of adaptive inhibitors when the target proteins share
conserved binding sites. Through the employment of this
developed method, we successfully found six new potent inhibitors
(,8.0 mM) of HpSK and MtSK. Two of the 65 kinase inhibitors
were also found to inhibit both HpSK and MtSK activity. The
finding that NSC45611 (1), NSC162535 (2), and NSC45612 (3)
were competitive inhibitors of ATP and shikimate suggests that
they belong to a novel class of shikimate kinase inhibitors. These
results illustrate a robust CoreSiMMap-based screening approach
for identifying selective kinase inhibitors.
The combined apo/closed CoreSiMMap analysis utilized here
is considered to be useful for induced-fit P-loop kinases. Of six
potent inhibitors, all except NSC45609 (7) have a higher rank in
the apo-form than in the closed-form CoreSiMMap-based scoring
analysis. Additionally, the top-ranked inhibitors according to the
apo-form CoreSiMMap-based scoring analysis often have larger
moieties (such as naphthalene or nitrobenzene) on both sides as
opposed to those with a relatively small moiety (e.g., amide or
aliphatic chain). The closed-form CoreSiMMap-based scoring
analysis has, nonetheless, yielded useful hits, including NSC45609
(7) and SPB01099 (11). Target proteins with dynamic induced-fit
forms, such as the P-loop SKs, represent a major limitation for the
structure-based screening approach.
The CoreSiMMap that shares consensus binding environments
among orthologous targets will be valuable for the development of
effective common inhibitors. Indeed, the inhibitors identified
herein had comparable IC50 values, docked poses, and competi-
tion properties for both HpSK and MtSK (Figs. 4, 5 and 6). More
importantly, this CoreSiMMap, which includes both nucleotide
and shikimate sites, specifically identified inhibitors that competed
with both substrates, whereas the two general kinase inhibitors
(AG538 (5) and GW5074 (12)) that did not compete well with the
shikimate site. Notably, the potent competitive shikimate inhibitors
have a common -N=N- moiety. A further lead optimization will
be required to verify the importance of this moiety.
The developed CoreSiMMap-based screening method is
database-independent. Comparable anchors were identified in
compounds from the Maybridge and NCI databases. Each of the
anchors also included similar chemical moieties. Nonetheless, the
derived proportion of these moieties was different because the
Maybridge and NCI databases contain heterogeneous distribution
of compounds. For example, the proportions of carboxyl,
sulfonate, and phosphate were significantly higher in compounds
from the NCI database than in those from the Maybridge
database. On the other hand, the derived model was sensitive to
binding-site properties, as revealed by the difference between the
apo- and closed-form models (Fig. 2). In summary, we anticipate
that the CoreSiMMap-based screening method will be useful for
discovering new inhibitors, investigating binding mechanisms, and
guiding lead optimization for orthologous targets.
Conclusions
We have developed a CoreSiMMap-based screening method to
derive conserved pocket-moiety environments (e.g., hot spots)
between orthologous targets and inhibitors from screening
compound libraries. Studies of site-directed mutagenesis and
analogues revealed that critical conserved interacting residues of
pocket-moiety interaction anchors participate in biological func-
tions. Experimental results reveal that the CoreSiMMap-based
screening method is database-independent and the CoreSiMMap
scoring method significantly outperformed the energy-based
scoring method, which is often used in docking tools. Furthermore,
we have successfully obtained several potent inhibitors and
revealed the binding mechanisms for MtSK and HpSK. The
CoreSiMMap is useful in providing biological insights and guiding
the process of drug discovery, including hit search and lead
optimization.
Materials and Methods
Overview of CoreSiMMap-based screening method
Figure 1 shows the main steps of the CoreSiMMap-based
screening method. For each orthologous target, we first docked
selected compounds into the binding site using GEMDOCK,
which is an in-house molecular docking program that uses PLP to
measure intermolecular potential energy between proteins and
compounds [29]. Our previous works showed that GEMDOCK
yields very comparable results to some other docking tools (e.g.,
DOCK, FlexX, and GOLD) when applied to 100 protein-ligand
complexes and some virtual screening targets [29,30]. Addition-
ally, GEMDOCK has been successfully applied to identify novel
inhibitors and binding sites for some targets [31–34]. After the
docking procedure, we used the top 2% (,6,000) of compounds
based on docking energy to analyze target-compound interaction
profiles (Fig. 1B and Fig. 3) to establish the site-moiety map
(Figs. 2A and 2B). Each anchor represented a local binding
environment with a specific physico-chemical property or phar-
macophore spot, which was derived by identifying statistically
significant interacting residues and compound moieties. The
CoreSiMMap (Figs. 2C and 2D) that consists of the aligned
anchors of orthologous proteins is generated by extracting the
consensus anchors from the orthologous SiMMaps.
Preparations of SK structures of four target proteins and
screening databases
Four structures of the target proteins were selected from Protein
Data Bank (PDB) for virtual screening. They were the apo-form
structure (PDB code: 1ZUH[19]) and the closed-form structure
(PDB code: 1ZUI[19]) of HpSK, and the apo-form structure (PDB
code: 2IYT[21]) and the closed-form structure (PDB code:
1ZYU[24]) of MtSK. The residues of the binding sites of these
four structures were prepared by the following steps. Firstly, the
apo-form and closed-form structures of MtSK were aligned to the
closed-form structure of HpSK using the structural alignment tool
[35]. The bound ligands (SKM and ACP) of HpSK were used to
determine the binding sites of these four structures. For each
structure, the residues of the binding site were obtained by
considering the protein atoms that were #10 A ˚ from these two
bound ligands.
We selected compounds from the Maybridge and NCI databases
for both HpSK and MtSK to establish the site-moiety maps and to
identify novel candidates. In total, 65,947 (Maybridge) and 236,962
Core Site-Moiety Map for Inhibitors and Mechanisms
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dalton were prepared for screening. In addition, we collected a
dataset of 37 orthologous target pairs with biological function
annotations (e.g., substrate binding, metal binding, and catalytic
residues) summarized from UniProt [36], Consurf server [37], and
Catalytic Site Atlas [38] (Table. S1) to verify the consensus anchors
residues that were derived using the CoreSiMMap-based screening
method. Experimental results reveal that the consensus anchors
often represent the conserved binding environments that are
involved in biological functions, such as substrate binding, metal
binding, or catalytic functions. Residues of consensus anchors of
these 37 orthologous pairs are often the key residues (i.e., substrate
binding residues, metal binding residues, catalytic residues, or high
conserved residues with Consurf conservation score 8 or 9) or key
anchors (i.e., anchors that contain key residues) (Fig. S4). For
example, D81, D84, and D201 of inositol-1-monophosphatase of
Methanocaldococcus jannaschii (D82, D85, and D200 in Archaeoglobus
fulgidus) are the consensus anchor residues and coordinate two metal
ions for catalysis [39]. Another example is the androgen receptor of
Homo sapiens, which is a target in the treatment of prostate cancer
[40]. Three residues (N705, R752, and T877) of the consensus
anchors are essential for the ligand binding [41]. These results
reveal that the consensus anchor residues often play important roles
in biological functions.
CoreSiMMap-based screening method
The main steps of the CoreSiMMap-based method for
producing SiMMaps and a CoreSiMMap from orthologous
targets are described as follows (Fig. 1):
N Virtual screening of orthologous targets. We used in-house
GEMDOCK program [23,29] to screen Maybridge (65,947
compounds) and NCI (236,962 compounds) databases for four
targets, including apo and closed forms of HpSK and MtSK.
GEMDOCK first assigned the formal charge and atom type
(i.e., donor, acceptor, both, or nonpolar) based on physico-
chemical property of each atom of both compounds and
binding sites. GEMDOCK then utilizes PLP to measure the
intermolecular potential energies between the binding sites
(rigid) and the compounds (flexible). Finally, these docked
compounds were ranked in order of energy. The top 2%
(,6,000) of compounds of each target were selected from the
screening results for subsequent protein-compound profiling. A
personal computer cluster (80 nodes, each with an Intel
Woodcrest 2.66 GHz processor and 4 GB of RAM) was used
to implement the docking procedure. On average, a docking
run (in which a compound was docked into a binding site of a
protein) took 63 s; therefore, docking 302,909 compounds into
these four proteins took about 11 days (,1,200,000 docking
runs).
N Selection of a diverse set of top-ranked compounds. To
maintain a wide range of potential functional groups in the
sampling of anchors, a cluster method was utilized to cluster
the top-ranked compounds. A hierarchical clustering method
that exploited the topological features of the compounds was
used. The topological features were generated by the atom pair
(AP) approach [42,43]. An AP was a substructure of a
compound and was presented as ‘‘atom type I – bond distance
– atom type J’’, where atom types I and J are the atom types of
atoms I and J, respectively, and bond distance is the number of
bonds measured along the shortest path between atoms I and
J. Atoms were classified into 10 types based on their chemical
properties (Table. S2), and there are 55 different combinations
of these 10 atom types in total. The value of the AP was set to 1
(ON) if the compound contained the substructure; otherwise,
the value was set to 0. Here, the maximum number of the
bonds was set to 15. Therefore, the number of APs was 825
(55615), and the topology of a compound was represented as a
string of 825 binary bits.
Subsequently, the AP binary strings of the top-ranked
compounds were used to cluster the compounds in a hierarchical
clustering procedure[44]. In the procedure, we firstly used the
Tanimoto coefficient (Tc) [43] to quantify the similarity between
two compounds (A and B). Tc was defined as
Tc(A,B)~
jNA\NBj
jNA|NBj
, ð1Þ
where |NA>NB| is the number of ON bits that are common to
both A and B, and | NA < NB | is the number of ON bits in either
A or B. Based on the Equation (1), the similarity matrix of the
compounds was generated, and applied to construct a dendrogram
by using complete linkage hierarchical clustering. The Tc
threshold that was used to group compounds was set to 0.9. The
compound with the lowest energy in each group was selected as
the representative compound for the group. Accordingly, we could
select a diverse set of compounds to ensure that many functional
groups would form the anchors.
N Profiling analysis of target-compound interactions (Fig. 1B and
Fig. 3). The profiles described the interactions (i.e., electrostatic
(E), hydrogen-bonding (H), and van der Waals (V) interactions)
between the diverse top-ranked compounds and the protein
residues, from which the anchors could be derived. The target-
compound interactions were identified by applying the PLP of
GEMDOCK program [29]. In the E or H profiles, a profile
entry was set to 1 if the compound forms electrostatic or
hydrogen-bonding interactions with the residue (green re-
gions); otherwise, the entry was set to 0 (black regions). I the V
profile, a profile entry was set 1 if the V energy was less than
24 kcal/mol.
N Identification of anchors (Fig. 1C). We identified consensus
interactions between residues and compound moieties from
the profiles. For an interacting residue, we used the Z-score to
measure the interacting conservation between the residue and
moieties. The interacting conservation is treated as a binomial
distribution, which is approximated as a normal distribution
when either p#0.5 and np.5o rp.0.5 and n(12p).5, where n
is the number of selected compounds and p is the probability of
forming an interaction. Theoretically, at least 500 compounds
should be selected to construct a target-compound interaction
profile. Spatially neighboring interacting residues and moieties
with statistically significant Z-score$1.645 are referred as an
anchor. A set of anchors derived from the target-compound
interaction profile can be used to establish a site-moiety map
for each orthologous target.
N Establishment of CoreSiMMap of orthologous targets
(Figs. 1D, 1E and Fig. 2). Firstly, the apo-form and closed-
form structures of orthologous proteins (HpSK and MtSK)
were aligned using a structural alignment tool [35]. The
superimposed SiMMaps (anchors) of the orthologous proteins
revealed an overlapping region of matched anchors which
form the CoreSiMMap (Figs. 2C and 2D). For compound x,
the CoreSiMMap-based score, combining anchor (CoreSiM-
Map) and PLP (GEMDOCK) scores, is defined as
CAS(x)~
Pa
i~1 wiASi(x){0:001E(x), where wi is the con-
servation of the anchor i on orthologous targets; ASi(x) is the
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anchors, and E(x) is the docked energy of the compound x. The
CoreSiMMap-based rank of compound x was obtained by
arranging the compounds in order of descending CAS(x). Table
S3 presents the parameters that are used to construct the
CoreSiMMap.
N Inhibition assay. We selected top-ranked compounds using
rank-based consensus scoring (RCS) for subsequent inhibitory
assay. The RCS of a compound x was calculated by combining
the ranks of m (apo/closed) forms of n orthologous targets as
follows: SR(x)~
Pn
i~1
Pm
k~1 RCki(x)=2mn, whereRCki(x) is
the CoreSiMMap-based rank of the compound x on the k
(apo/closed) form of target i. Here, m and n are 2. We obtained
the RCS rank of the compound x by arranging the compounds
in order of ascending SR(x).
N Refinement of CoreSiMMaps. Active and inactive compounds
from the enzyme inhibition assay were used to evaluate and
refine the CoreSiMMaps.
Cloning, expression, and purification of M. tuberculosis
shikimate kinase (MtSK) and H. pylori shikimate kinase
(HpSK)
AroK, which encodes MtSK, was amplified from the chromo-
somal DNA of Mycobacterium tuberculosis str. Haarlem with
PCR using pfu DNA polymerase. Primers (MtSK-F (forward),
59- CGCGGATCCATGGCACCCAAAGCGGTTCTCGTCG -
39; MtSK-R (reverse), 59-AAACTGCAGTCATGTGGCCGC
CTCGCTGGGGCTG-39) that contain sequences for the BamHI
and PstI sites, respectively, were designed based on the nucleotide
sequence of the reported MtSK gene of M. tuberculosis (accession
number AASN01000059; Genome Project: 17353). The amplified
fragment was inserted into the pET28a expression vector to
generate pET28a-MtSK containing an N-terminal six-histidine
tag (His6) for purification purposes. The recombinant MtSK in E.
coli BL-21 (DE3) cells was induced with 1 mM isopropyl-b-D-
thiogalactopyranoside (IPTG) at 16uC. Bacterial pellets were
fractionated, and soluble proteins in cytosolic fractions were
collected. The expressed MtSK protein with a His6 tag was
purified by immobilized-nickel ion chromatography, followed by
Superdex-75 gel filtration chromatography (Pharmacia), and then
analyzed using SDS-PAGE to verify its purity. The cloning and
purification of HpSK were based on previous methods [19].
Preparation of mutant HpSKs
Site-directed mutagenesis was performed using the overlap
extension PCR [45] method with the plasmid pQE30-HpSK as the
template. All the mutations were confirmed by sequencing of the
whole ligated PCR fragment. Mutant proteins were expressed and
purified by the same procedures as described for the wild-type HpSK.
Enzymatic activity assay and analysis of inhibitor kinetics
Shikimate kinase activity was determined by coupling the
release of ADP from the SK-catalyzed reaction to the oxidation of
NADH using pyruvate kinase (EC 2.7.1.40) and lactate dehydro-
genase (EC 1.1.1.27) as coupling enzymes [46]. Shikimate-
dependent oxidation of NADH was measured by monitoring the
decrease in A340 (e=6,200 M
21 cm
21). The assay was carried
out at 25uC in a mixture of 100 mM Tris-HCl buffer, pH 7.5,
50 mM KCl, 5 mM MgCl2, 1.6 mM shikimic acid, 2.5 mM ATP,
1 mM phosphoenolpyruvate (PEP), 0.1 mM NADH, 2.5 units of
pyruvate kinase per ml, and 2.7 units of lactate dehydrogenase per
ml. All assays were conducted in a 96-well microplate and
analyzed with a spectrophotometer (FLUOstar OPTIMA, BMG
LABTECH).
Stock solutions of compounds were prepared in dimethylsulf-
oxide (DMSO). Each set of measurements included 10% DMSO
as a negative control. Approximately 80 nM enzyme was added to
a reaction of 200 ml containing compounds. The initial velocities
of enzyme activity were determined in the presence of various
concentrations of test compounds to investigate the dose-
dependent inhibition effects. The IC50 values of these compounds
were obtained by fitting the data to a sigmoid dose-response
equation in GraphPad Prism 4.
After the preliminary screening, the inhibitor modality was
determined by measuring the effects of inhibitor concentrations on
the enzymatic activity as a function of substrate concentration. In
the inhibition experiment in which the ATP concentration was
fixed at 2.5 mM, shikimate was a varied substrate (0.06, 0.12,
0.24, 0.48, and 0.96 mM) when the concentration of inhibitor was
varied from 0 to 50 mM. In parallel, in the inhibition experiment
in which the shikimate concentration was fixed at 1.6 mM, ATP
was a varied substrate (0.06, 0.12, 0.24, 0.48, and 0.96 mM) when
the concentration of inhibitor was varied from 0 to 50 mM. A
nonlinear least square-fitting algorithm was applied to the
absorbance data to determine the kinetic mechanism data.
Supporting Information
Figure S1 Site-moiety maps of apo-form (A) HpSK and
(B) MtSK. Each anchor represents one of three binding
environments (electrostatic: blue; hydrogen-bonding: green; van
der Waals: black). The distribution of identified chemical moieties
for each anchor is shown as a pie chart. In HpSK, H1, V1, and
H2 are situated at the nucleotide site, while H3, V2, and E1 are at
the shikimate site. In MtSK, H1, V1, V3, and H2 are at the
nucleotide site, while H3, V2, and E1 are at the shikimate site.
(TIF)
Figure S2 Site-moiety maps of closed-form (A) HpSK
and (B) MtSK. Each anchor represents one of three binding
environments (electrostatic: blue; hydrogen-bonding: green; van
der Waals: black). The distribution of identified chemical moieties
for each anchor is shown as a pie chart. In HpSK, H1, V1, and
H2 are situated at the nucleotide site, while H3, V2, and E1 are at
the shikimate site. In MtSK, H1, V1, V3, and H2 are at the
nucleotide site, while H3, V2, and E1 are at the shikimate site.
(TIF)
Figure S3 (A) Circular dichroism profiles of HpSK in the
presence or absence of various ligands. (B) Superimposition of apo
and closed HpSK structures. Apo and closed structures are shown
in red and green, respectively. Shikimate and phosphate are
represented as sticks. The carbon, oxygen and phosphorus atoms
are colored green, red, and orange, respectively. Pharmacophore
spots of the apo (C) and closed (D) forms of HpSK.
(TIF)
Figure S4 (A) The percentages of key residues of consensus
anchor residues and non-consensus anchor residues derived from
the 37 orthologous target pairs. Key residues are substrate binding
residues, metal binding residues, catalytic residues, or high
conserved residues. (B) The percentages of key anchors of
consensus anchors and non-consensus anchors derived from the
37 orthologous target pairs. Key anchors are anchors that contain
one or more key residues.
(TIF)
Table S1 Summary of 37 pairs of orthologous targets.
(DOC)
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Table S3 Parameters used in the CoreSiMMap.
(DOC)
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